Please login to the form below

Not currently logged in
Email:
Password:

EU approval for Tamiflu use in children

Roche antiviral to be used as a preventative measure against influenza

Roche's antiviral, Tamiflu, has received approval from European regulators to be used for the prevention of influenza in children aged from one to 12 years, mirroring a move made in the US back in December.

Tamiflu is seen as the first line of defence against the threat of an avian flu pandemic and is currently being stockpiled by governments around the world.

ìThe influenza season is just starting in the northern hemisphere and Roche plans to make Tamiflu available to prevent influenza in very young children who are particularly vulnerable during an outbreak of the disease,î said Roche pharmaceutical division's chief executive William Burns. ìThis is particularly helpful in the family setting when one member of the family catches influenza - using Tamiflu for prevention will stop the spread of the disease to other family members.î

Roche said children are three times more likely to get sick with the flu. On average, one in 10 adults and one in three children are affected by influenza every year.

The firm has already expanded its production capacity for Tamiflu several times to try and meeting the escalating demand for it from countries around the world. European countries are aiming to stockpile enough of the drug for use in between 20 and 40 per cent of their populations.

Analysts expect sales of Tamiflu to immensely boost Roche's pharmaceutical sales in 2005 by SwFR1bn, helping contribute to a healthy rise in operating profits.

Analysts polled by Reuters predicted the Basel-based company to report a 23 per cent increase year-on-year in pharmaceutical sales, when it reports its full-year figures on Wednesday (February 1).

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics